|
|
Blood, 1 July 2004, Vol. 104, No. 1, pp. 92-99.
Prepublished online as a Blood First Edition Paper on March 18, 2004; DOI 10.1182/blood-2003-10-3433.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis
Marco Rusnati,
Maura Camozzi,
Emanuela Moroni,
Barbara Bottazzi,
Giuseppe Peri,
Stefano Indraccolo,
Alberto Amadori,
Alberto Mantovani, and
Marco Presta
From the Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy; Mario Negri Institute, Milan, Italy; the Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy; and the Institute of General Pathology, University of Milan, Milan, Italy.
The long pentraxin PTX3 is a soluble pattern recognition receptor produced by monocytes and endothelial cells that plays a nonredundant role in inflammation. Several pathologic conditions are characterized by local production of both PTX3 and the angiogenic fibroblast growth factor-2 (FGF2). Here, solid-phase binding assays demonstrated that PTX3 binds with high affinity to FGF2 but not to a panel of cytokines and growth factors, including FGF1, FGF4, and FGF8. Accordingly, PTX3 prevented 125I-FGF2 binding to endothelial cell receptors, leading to specific inhibition of FGF2-induced proliferation. PTX3 hampered also the motogenic activity exerted by endogenous FGF2 on a wounded endothelial cell monolayer. Moreover, PTX3 cDNA transduction in FGF2-transformed endothelial cells inhibited their autocrine FGF2-dependent proliferation and morphogenesis in vitro and their capacity to generate vascular lesions when injected in nude mice. Finally, PTX3 suppressed neovascularization triggered by FGF2 in the chick embryo chorioallantoic membrane with no effect on physiologic angiogenesis. In contrast, the short pentraxin C-reactive protein was a poor FGF2 ligand/antagonist. These results establish the selective binding of a member of the pentraxin superfamily to a growth factor. PTX3/FGF2 interaction may modulate angiogenesis in various physiopathologic conditions driven by inflammation, innate immunity, and/or neoplastic transformation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M.E. Suliman, A.R. Qureshi, J.J. Carrero, P. Barany, M.I. Yilmaz, S. Snaedal-Jonsdottir, A. Alvestrand, O. Heimburger, B. Lindholm, and P. Stenvinkel
The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality
QJM,
May 1, 2008;
101(5):
397 - 405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Inforzato, V. Rivieccio, A. P. Morreale, A. Bastone, A. Salustri, L. Scarchilli, A. Verdoliva, S. Vincenti, G. Gallo, C. Chiapparino, et al.
Structural Characterization of PTX3 Disulfide Bond Network and Its Multimeric Status in Cumulus Matrix Organization
J. Biol. Chem.,
April 11, 2008;
283(15):
10147 - 10161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Duluc, Y. Delneste, F. Tan, M.-P. Moles, L. Grimaud, J. Lenoir, L. Preisser, I. Anegon, L. Catala, N. Ifrah, et al.
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells
Blood,
December 15, 2007;
110(13):
4319 - 4330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Cotena, V. Maina, M. Sironi, B. Bottazzi, P. Jeannin, A. Vecchi, N. Corvaia, M. R. Daha, A. Mantovani, and C. Garlanda
Complement Dependent Amplification of the Innate Response to a Cognate Microbial Ligand by the Long Pentraxin PTX3
J. Immunol.,
November 1, 2007;
179(9):
6311 - 6317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tranguch, A. Chakrabarty, Y. Guo, H. Wang, and S. K Dey
Maternal Pentraxin 3 Deficiency Compromises Implantation in Mice
Biol Reprod,
September 1, 2007;
77(3):
425 - 432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Camozzi, M. Rusnati, A. Bugatti, B. Bottazzi, A. Mantovani, A. Bastone, A. Inforzato, S. Vincenti, L. Bracci, D. Mastroianni, et al.
Identification of an Antiangiogenic FGF2-binding Site in the N Terminus of the Soluble Pattern Recognition Receptor PTX3
J. Biol. Chem.,
August 11, 2006;
281(32):
22605 - 22613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bottazzi, A. Bastone, A. Doni, C. Garlanda, S. Valentino, L. Deban, V. Maina, A. Cotena, F. Moalli, L. Vago, et al.
The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility
J. Leukoc. Biol.,
May 1, 2006;
79(5):
909 - 912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Rattazzi, E Faggin, B Bertipaglia, and P Pauletto
Innate immunity and atherogenesis
Lupus,
September 1, 2005;
14(9):
747 - 751.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Camozzi, S. Zacchigna, M. Rusnati, D. Coltrini, G. Ramirez-Correa, B. Bottazzi, A. Mantovani, M. Giacca, and M. Presta
Pentraxin 3 Inhibits Fibroblast Growth Factor 2-Dependent Activation of Smooth Muscle Cells In Vitro and Neointima Formation In Vivo
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2005;
25(9):
1837 - 1842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Latini, A. P. Maggioni, G. Peri, L. Gonzini, D. Lucci, P. Mocarelli, L. Vago, F. Pasqualini, S. Signorini, D. Soldateschi, et al.
Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction
Circulation,
October 19, 2004;
110(16):
2349 - 2354.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
